EPA modifies regulations for chemical storage

November 22, 2019

The Environmental Protection Agency on Thursday released modified standards regarding the storage of dangerous chemicals. Proponents of the change say the new standards will improve public safety, while opponents argue that the revisions “undo critical safety measures” put into place under the Obama Administration in response to a 2013 chemical fertilizer explosion that killed more than a dozen people in Texas. The Risk Management Program Reconsideration Rule, as the new standard is known, removes the requirement that companies publicly disclose the chemicals stored on their grounds, rescinds third-party audits and incident investigation root cause analysis mandates and modifies emergency planning and response requirements.

Spotlight

Cerenis Therapeutics

Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001). CER-001 has successfully completed Phase I. The product is designed to rapidly regress atherosclerotic plaque among patients at high risk of cardiovascular events. It is based on Cerenis’ multiple breakthroughs in the science of HDL, which have allowed the identification and development of highly potent and pure HDL particles.

OTHER ARTICLES

Transporting biological and chemical materials - what you need to know

Article | February 13, 2020

The landscape of biological and chemical logistics has changed rapidly - as have the regulatory frameworks around it. What has not necessarily kept pace is the end-user understanding of the nature of these logistical processes, their opportunities and their constraints. Twenty years ago, the transmission of biological and chemical materials was limited to a small range of organisations: usually national and international research companies, hospitals, major university departments, police and military departments with forensic responsibilities.

Read More

Setting record straight on testing harm in chemicals

Article | February 13, 2020

The modern world is built on chemicals, be it the medicines we use, or cleaning fluids, crop protection products, or the raw materials for everything from laptops and mobile phones to clothes and furniture. Across all, we have created an entire modern society with chemicals, and, as a result, constantly stretched the size of the world population we can feed, clothe and shelter. Yet, balancing all the gains from the modern chemistry around us against any negative environmental and human impact has been a rising concern, making for ever greater focus on testing and on risk assessment.

Read More

Why chemical characterization is the best way to assess patient risk

Article | February 11, 2020

Everyone is very familiar with the phrase when buying a house: All that really matters are three things - location, location, and location. This same principle applies to extractables and leachables chemistry analysis – the three things that truly matter are identification, identification, and identification. The greatest growth in the past ten years in demonstrating the safety of medical devices and container closure systems for drugs has been using analytical chemistry to determine what chemicals can leach from the device and what the patient is exposed to during its intended use.

Read More

How Chemical Companies Benefit from the Experience Economy

Article | February 10, 2020

To feel or experience from a business engagement started with customer experience mainly in the consumer products business. Today it has extended to even knowledge industries like the chemical industry where experiencing or feeling can be leveraged to include all stake holders from customers primarily to employees to supply chain people & suppliers and all else. With digital technologies this has become easier than before. The benefits from promoting the ‘feel’ or ‘experience’ emotion could be multifarious for the chemical industry as described in this article.

Read More

Spotlight

Cerenis Therapeutics

Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001). CER-001 has successfully completed Phase I. The product is designed to rapidly regress atherosclerotic plaque among patients at high risk of cardiovascular events. It is based on Cerenis’ multiple breakthroughs in the science of HDL, which have allowed the identification and development of highly potent and pure HDL particles.

Events